Jim Cramer And Bob Lang Go “Off The Charts” And Look At Three Biotech Buys

By | July 17, 2018

Bob Lang, the founder of ExplosiveOptions.net and part of TheStreet.com’s Trifecta Stocks newsletter team gave his technical take on three stocks in the biotechnology sector, on the “Off the Charts” segment of Mad Money tonight.

Cramer’s charts suggest big-name biotech stocks Gilead and Celgene have more room to run from CNBC.

Gilead Sciences (GILD), Celegene (CELG), and Illumina (ILMN) have been laggards in the biotech space but Bob believes and Jim agrees, they are prepared to head higher.

Leave a Reply